MedTrace Logo

Ischemia Care Biomarkers of Acute Stroke Etiology (BASE)

NCT02014896 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1750

Last updated 2020-07-08

No results posted yet for this study

Summary

The proposed study will validate the clinical use of new biomarker blood tests to identify blood components that may differentiate between diverse stroke etiologies and clinical outcomes as listed below:

1. Differentiate between cardioembolic and large artery atherosclerotic ischemic strokes, when hemorrhagic stroke is ruled out.
2. In cases of ischemic strokes of unknown or "cryptogenic" etiology, determine the ability of biomarker blood tests to predict etiology between cardioembolic and large artery atherosclerotic.
3. In cases of cardioembolic ischemic stroke, further differentiation of cardioembolic ischemic strokes into those caused by atrial fibrillation (AF) and those not caused by AF.
4. Differentiate "transient ischemic attacks" (TIAs) from acute ischemic strokes.
5. Differentiate TIAs from non-ischemic "transient neurological events" (TNE) with similar symptoms.

Conditions

Interventions

OTHER

Biomarker blood draw

Comparison of gene expression profiles using RNA isolated from whole blood.

Sponsors & Collaborators

  • Ischemia Care LLC

    lead INDUSTRY

Principal Investigators

  • Frank Peacock, MD · Ischemia Care

  • Edward Jauch, MD · Medical University of South Carolina

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-12-31
Primary Completion
2019-11-30
Completion
2020-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02014896 on ClinicalTrials.gov